Innovating Beyond Ochsner Custom Case Solution & Analysis

Part 1: Evidence Brief

Prepared by: Business Case Data Researcher

Financial Metrics

• Total System Revenue: Approximately 3 billion dollars annually for the Ochsner Health System (Exhibit 1).
• Chronic Disease Impact: Chronic conditions account for 80 percent of total healthcare spending in the United States (Paragraph 4).
• Digital Medicine Performance: 71 percent of patients in the digital hypertension program achieved blood pressure control within 90 days, compared to 31 percent in the traditional care group (Paragraph 12).
• Diabetes Management: Patients in the digital program saw a 1.0 percent reduction in HbA1c levels (Paragraph 14).
• Investment: Ochsner allocated significant internal capital to launch innovationOchsner (iO) in 2015 (Paragraph 8).

Operational Facts

• Headcount: Ochsner Health System employs over 25000 individuals including 1300 physicians (Paragraph 2).
• Infrastructure: The system includes 40 owned, managed, or affiliated hospitals and more than 100 health centers (Paragraph 2).
• iO Structure: A dedicated innovation lab focused on digital health, big data, and precision medicine (Paragraph 8).
• Patient Volume: Over 3000 patients enrolled in the Digital Medicine program by 2017 (Paragraph 15).
• Technology Stack: Integration with the Epic Electronic Health Record system for real-time data monitoring (Paragraph 10).
• O Bar: Physical retail locations within hospitals providing tech support and health apps to patients (Paragraph 18).

Stakeholder Positions

• Warner Thomas (CEO): Focuses on the transition from volume to value and seeks ways to export Ochsner intellectual property to ensure long-term sustainability (Paragraph 5).
• Richard Milani (Chief Clinical Transformation Officer): Advocates for technology-enabled proactive care models to replace reactive physician visits (Paragraph 7).
• Pete November (Chief Administrative Officer): Concerned with the legal and operational structures required to scale innovations externally (Paragraph 22).
• External Health Systems: Potential customers who need similar results but may view Ochsner as a competitor (Paragraph 25).

Information Gaps

• Specific Profit and Loss statements for the iO unit as a standalone entity.
• Detailed customer acquisition costs for selling Digital Medicine to non-Ochsner providers.
• Retention rates for patients in the Digital Medicine program beyond the first 12 months.
• The exact licensing fee structure proposed for the external version of the software.

Part 2: Strategic Analysis

Prepared by: Market Strategy Consultant

Core Strategic Question

• How can Ochsner transition from an integrated delivery network to a healthcare technology provider without compromising its clinical mission or operational focus?
• What is the optimal commercialization model to scale digital health solutions to external competitors?

Structural Analysis

The shift toward value-based care creates a structural demand for chronic disease management. Using a Jobs-to-be-Done lens, the job for health systems is to reduce the cost of care for high-risk populations. Ochsner solved this internally by replacing periodic office visits with continuous remote monitoring. However, the Value Chain analysis reveals a bottleneck: the current model is deeply embedded in the clinical workflow of Ochsner. To sell this as a product, Ochsner must decouple the technology from its own medical staff.

Strategic Options

Option 1: The Managed Service Provider Model. Ochsner provides both the technology and the clinical staff to monitor external patients.
Rationale: Ensures quality and clinical outcomes remain high.
Trade-offs: Extremely difficult to scale due to state licensing laws for clinicians and high overhead.
Resource Requirements: Massive expansion of the remote nursing pool and legal compliance teams.

Option 2: Pure SaaS Licensing. Ochsner licenses the Digital Medicine software and the O Bar concept to other systems.
Rationale: High margins and rapid scalability.
Trade-offs: Relies on the ability of the customer to execute the clinical change. If the customer fails, the Ochsner brand suffers.
Resource Requirements: Significant investment in software engineering and customer success teams.

Option 3: Independent Venture Spin-off. Create a separate corporate entity for iO with external private equity or venture capital.
Rationale: Allows the new entity to hire tech talent at market rates and removes the competitor bias when selling to other health systems.
Trade-offs: Loss of direct control and potential friction in the feedback loop between Ochsner clinicians and the tech team.
Resource Requirements: Legal restructuring and a dedicated sales force.

Preliminary Recommendation

Pursue Option 3. The internal culture of a non-profit hospital system is fundamentally incompatible with the speed and risk profile of a technology startup. By spinning off iO, Ochsner can retain a significant equity stake while allowing the entity to compete for talent and customers globally. This move protects the core hospital business from the financial volatility of a tech venture while providing the capital necessary to scale the Digital Medicine platform.

Part 3: Implementation Roadmap

Prepared by: Operations and Implementation Planner

Critical Path

The transition to an external-facing entity requires three distinct workstreams. First, an Intellectual Property audit must identify which algorithms and workflows are proprietary to Ochsner. Second, the technical team must build a multi-tenant version of the Digital Medicine platform that functions independently of the Ochsner Epic instance. Third, a pilot program with a non-competing health system in a different geographic region must validate the model.

• Months 1-3: Legal formation of the new entity and transfer of IP.
• Months 4-6: Development of a standardized implementation kit for external partners.
• Months 7-12: Launch of the first external pilot with a 500-patient cohort.

Key Constraints

• EHR Interoperability: Most health systems use different versions of Epic or Cerner. The ability to push and pull data without manual entry is the primary technical hurdle.
• Regulatory Compliance: Operating across state lines requires the new entity to navigate varying medical practice acts and data privacy laws.
• Clinical Inertia: External physicians will resist a platform that they perceive adds more work to their day or interferes with their patient relationships.

Risk-Adjusted Implementation Strategy

To mitigate the risk of clinical failure, the initial offering should be a hybrid model. Ochsner will provide the software and a consulting team to train the staff of the partner. This reduces the operational burden on the new entity while ensuring the partner follows the proven Ochsner clinical protocol. Success will be measured by the ability of the partner to achieve a 60 percent control rate in their hypertension population within the first year. If this target is missed, the implementation team must pivot to a more intensive managed service model until the partner reaches proficiency.

Part 4: Executive Review and BLUF

Prepared by: Senior Partner and Executive Reviewer

BLUF

Ochsner must spin off innovationOchsner into an independent commercial entity immediately. The current internal structure prevents the technology from scaling at the pace of the market. While the Digital Medicine program has delivered superior clinical results, its growth is capped by the balance sheet and regional footprint of the parent system. An independent entity will resolve the inherent conflict of interest when selling to other providers and allow for the aggressive capital infusion needed to dominate the remote patient monitoring space. Delaying this separation will result in the loss of first-mover advantage as well-capitalized tech competitors enter the market.

Dangerous Assumption

The most dangerous assumption is that external health systems possess the organizational discipline to replicate the results of Ochsner. The success of Digital Medicine is not just the software; it is the culture of clinical accountability at Ochsner. If external partners fail to change their internal workflows, the software will become shelfware, and the reputation of Ochsner will be damaged.

Unaddressed Risks

Unconsidered Alternative

The analysis overlooked a white-label partnership with a national payer or pharmacy chain (such as CVS or UnitedHealth). Instead of selling to fragmented health systems, Ochsner could integrate its Digital Medicine platform directly into a national insurance plan. This would provide instant scale and bypass the need for a large enterprise sales force targeting individual hospitals.

VERDICT: APPROVED FOR LEADERSHIP REVIEW